Poseida Therapeutics To Present New Clinical Data From Phase 1 Study Of Allogeneic CAR-T P-BCMA-ALLO1 In Patients With Relapsed/Refractory Multiple Myeloma At 21st International Myeloma Society Annual Meeting; Initiation Of P-BCMA-ALLO1 Phase 1b Clinical Trial In Patients With Multiple Myeloma, Generated $20M Payment From Roche
Portfolio Pulse from Benzinga Newsdesk
Poseida Therapeutics is set to present new clinical data from its Phase 1 study of the allogeneic CAR-T therapy P-BCMA-ALLO1 at the International Myeloma Society Annual Meeting. The initiation of a Phase 1b trial has generated a $20 million payment from Roche.
September 05, 2024 | 1:14 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Poseida Therapeutics will present new data on its P-BCMA-ALLO1 therapy at the IMS Annual Meeting. The initiation of a Phase 1b trial has resulted in a $20 million payment from Roche, highlighting the progress and potential of their CAR-T program.
The presentation of new clinical data and the $20 million payment from Roche are positive indicators of Poseida's progress in developing its CAR-T therapy, likely boosting investor confidence and stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Roche has made a $20 million payment to Poseida Therapeutics for the initiation of a Phase 1b trial of P-BCMA-ALLO1, reflecting its investment in the development of innovative cancer therapies.
Roche's payment to Poseida signifies its commitment to advancing cancer therapies, which could positively impact its reputation and investor sentiment.
CONFIDENCE 85
IMPORTANCE 60
RELEVANCE 70